DIAGNAMED HLDGS CORP - DGNMF STOCK NEWS

DiagnaMed Holdings (CSE: DMED, OTCQB: DGNMF) has announced two significant corporate updates. First, Elyssia Patterson has resigned from the company's board of directors. Second, the company has issued 1,000,000 stock options to consultants with an exercise price of $0.05 per common share. These options have a five-year expiration term and will vest in four equal installments over a one-year period, with the first quarter vesting at three months and subsequent quarters vesting at six, nine, and twelve months from the grant date.

DiagnaMed Holdings Corp. (CSE: DMED, OTCQB: DGNMF) has announced a strategic partnership with Québec Innovative Materials Corp. (QIMC) to implement DiagnaMed's hydrogen extraction technology at QIMC's Ville Marie Hydrogen Project in Québec.

The collaboration centers on DiagnaMed's patented technology (WO2023044149A1), developed by Dr. Qingwang Yuan at Texas Tech University. This innovative method combines hydraulic fracturing with electromagnetic wave heating to extract hydrogen from various sources, including light oil, gas, shale reservoirs, and ultramafic rock formations.

The technology promises hydrogen production costs as low as $0.86 per kilogram, aligning with the U.S. Department of Energy's goal of achieving $1/kg hydrogen production by 2031. As part of the agreement, QIMC will receive 2,000,000 shares of DMED.

DiagnaMed Holdings (CSE: DMED, OTCQB: DGNMF), a frontrunner in hydrogen-producing technologies and AI medical applications, has announced a strategic partnership with Texas Tech University. This collaboration aims to commercialize a revolutionary technology (WO2023044149A1) for producing hydrogen directly from petroleum reservoirs and natural hydrogen fields.

Developed by Dr. Qingwang Yuan of the HOPE Group at Texas Tech, the technology combines hydraulic fracturing with electromagnetic wave heating to generate hydrogen from light oil, gas, and shale reservoirs, as well as ultramafic rock formations. With production costs potentially as low as $0.86 per kilogram, it aligns with the U.S. Department of Energy's goal of achieving $1/kg hydrogen by 2031.

Fabio Chianelli, Chairman and CEO of DiagnaMed, highlighted the technology's potential to transform over 25,000 active oil and gas fields globally and repurpose 2-3 million abandoned wells in the U.S. This innovation not only addresses global clean energy demands but also aims to reduce greenhouse gas emissions and deliver cost-effective, carbon-zero hydrogen.

Supported by a Techno-Economic Analysis from Argonne National Laboratory, this first-of-its-kind technology enhances energy efficiency and reduces costs and carbon footprints. As global hydrogen demand is expected to grow significantly, DiagnaMed’s partnership with Texas Tech positions it as a leader in the clean energy sector.

DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) has partnered with EIREX to develop and commercialize a novel hydrogen extraction technology from water. The EIREX technology aims to produce hydrogen at $0.25 per kilogram for pilot prototypes and $0.10 per kilogram for commercial units, significantly lower than the industry's 2030 target of $2 per kilogram. The global hydrogen market, valued at $170.14 billion in 2023, is expected to grow at a 9.3% CAGR through 2030. The collaboration focuses on developing commercial pilot prototypes and establishing partnerships with healthcare facilities for operational and medical treatment purposes.

DiagnaMed Holdings Corp (CSE: DMED) (OTCQB: DGNMF) has announced two key corporate actions: First, the company has granted 4.5 million stock options to directors, officers, and consultants at $0.05 per share, with a five-year expiration and quarterly vesting schedule over one year. Second, the board has approved a shares-for-debt settlement of $67,800 through the issuance of 1,356,000 common shares at $0.05 per share to an arm's length creditor.

DiagnaMed Holdings Corp. (OTCQB: DGNMF) has filed a provisional patent application with the U.S. Patent and Trademark Office for novel methods of producing molecular hydrogen to treat neurological and mental health disorders. The patent covers pharmaceutical-based methods and compositions targeting conditions like Dementia, Parkinson's disease, Depression, and Anxiety. The company plans to partner with research institutions and life sciences companies for manufacturing and clinical research, with the product expected to be ready by December 2024. The global hydrogen generation market was valued at $170.14 billion in 2023, with a projected CAGR of 9.3% through 2030. Over 2,000 scientific publications support molecular hydrogen's therapeutic potential, highlighting its antioxidant and neuroprotective properties.

DiagnaMed Holdings Corp. (CSE: DMED, OTCQB: DGNMF) announces its strategic initiative in advancing molecular hydrogen therapies for brain health. The global hydrogen generation market, valued at USD 170.14 billion in 2023, is projected to grow at a 9.3% CAGR from 2024 to 2030. Over 2,000 scientific publications and 100+ human studies support molecular hydrogen's therapeutic potential, demonstrating antioxidant, anti-inflammatory, and neuroprotective effects. The company plans to develop and commercialize novel molecular hydrogen therapies for neurological disorders, offering various doses and administration methods. DiagnaMed aims to partner with companies exploring 'white' hydrogen sources and license technologies from academic institutions.

DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) is expanding its BRAIN AGE® Brain Health AI Platform to create a potential drug discovery and clinical research AI platform. The company is leveraging EEG data from previous and future research studies to accelerate clinical trial development and discover novel treatments for neurological, psychiatric, and infectious diseases.

BRAIN AGE® estimates brain age by analyzing brain-wave activity and can assess if a brain is aging atypically or if a person is in the early stage of cognitive decline. The platform has been clinically validated in a peer-reviewed paper published in Frontiers in Neuroergonomics, demonstrating its potential for large-scale screening and brain optimization.

The expanded platform aims to accelerate patient recruitment for clinical trials, enhance data analysis, and support drug development decisions. It can also help individuals seek personalized diagnostics and interventions to potentially decrease cognitive decline.

DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) is offering its BRAIN AGE® Brain Health AI Platform to investigate the impact of weight loss drugs, like Semaglutide, on brain function. This comes after a study showed Semaglutide doesn't negatively impact brain health and is associated with lower cognitive problems and less nicotine dependence.

The global market for obesity drugs is expected to reach $105 billion by 2030. BRAIN AGE® aims to identify potential brain health issues and gain insights into brain function while taking weight loss drugs. The platform uses a low-cost EEG headset and machine learning to estimate brain age and assess cognitive health.

Clinical validation of BRAIN AGE® has shown promising results in screening for age-related vulnerabilities and assessing the risk of developing Alzheimer's disease and other neurological issues.